The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Cell and gene therapies offer unprecedented hope to a growing number of patients. In the treatment of refractory/relapsed malignancy, a single dose may be lifesaving. Payment models may threaten the commercial viability of these therapies. Incremental cost effectiveness analyses have supported manufacturers’ high retail prices for these agents. Payers, on the other hand, are hesitant to pay for such an expensive agent when the benefit may be enjoyed by a competitor to insurance churn. Patients are unlikely to be able to cover such high-cost therapies out of pocket. Operational challenges are also a threat to successful implementation of these therapies. Commercialization of these agents has exposed uncompensated effort throughout the procurement cycle. This session aims to highlight different perspectives on financial challenges of cell and gene therapies and prompt the investigation of innovative solutions.
To view Spanish or English subtitles, click the "CC" box in the video player. Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
Describe common financial challenges faced by academic medical centers with respect to cell and gene therapies
Describe common financial challenges faced by payers with respect to cell and gene therapies
Discuss possible solutions or future directions for cell and gene therapy payment
Moderator(s):
Andrew
Fesnak,
MD,
Perelman School of Medicine, University of Pennsylvania
All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
AM21-52: Financial Challenges in the Age of Cell and Gene Therapies Evaluation